Health Catalyst HCAT Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss at other companies
Other financials
Where this comes from
Reported directly by Health Catalyst in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss.
The official record: Health Catalyst’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Health Catalyst's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Health Catalyst's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
- Health Catalyst (HCAT) reported debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss of $100.14M in Q1 2026.
- What is the long-term trend for Health Catalyst's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
- Over 5 years (2020 to 2025), Health Catalyst's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss has grown at a -19.0% compound annual growth rate (CAGR), from $258.29M to $89.93M.